期刊文献+

喹硫平治疗伴发抑郁症状精神分裂症的临床效果 被引量:3

下载PDF
导出
摘要 目的探讨喹硫平对伴有抑郁症状精神分裂症患者的疗效。方法将98例精神分裂症患者随机分为喹硫平组(30例)、利培酮组(35例)、奋乃静组(33例),疗程8周。分别于治疗前、治疗2、4、8周末采用阳性和阴性症状量表(PANSS)、卡尔加里精神分裂症抑郁量表(CDSS)评定疗效,用治疗时副反应量表(TESS)评定安全性。结果在治疗8周末时三组PANSS评分、CDSS评分均有显著改善,喹硫平组与利培酮组比较差异无统计学意义,两组均低于奋乃静组(P<0.05);治疗2周末喹硫平组CDSS评分较利培酮组显著改善,差异有统计学意义(P<0.05);治疗4、8周末两组疗效相当,各时间点两组CDSS评分与奋乃静组差异有统计学意义(P<0.05)。喹硫平组与利培酮组副作用均较少,低于奋乃静组。结论喹硫平与利培酮治疗精神分裂症疗效相当,在阴性症状及伴随的抑郁症状方面改善均优于奋乃静,喹硫平在改善抑郁症状时起效更快,安全性更高。
出处 《宁夏医学杂志》 CAS 2012年第12期1266-1268,共3页 Ningxia Medical Journal
  • 相关文献

参考文献9

  • 1张作记.行为医学量表手册[M]北京:中华医学电子音像出版社,2005355-359.
  • 2张鸿燕,肖卫东.评价精神分裂症的抑郁症状——卡尔加里精神分裂症抑郁量表[J].国际精神病学杂志,2006,33(1):8-12. 被引量:36
  • 3张明园.精神科评定量表手册[M]长沙:湖南科学技术出版社,1998121-126.
  • 4Addington D,Addington J,Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics[J].Schizophrenia Research,1994,(03):239-244.
  • 5吴刚,王云,罗颖.齐拉西酮治疗精神分裂症40例临床疗效观察[J].中国现代药物应用,2008,2(20):42-43. 被引量:5
  • 6Weiden PJ,Daniel DG,Simpson G. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone[J].Journal of Clinical Psychopharmacology,2003,(06):595-600.
  • 7沈渔邨.精神病学[M]北京:人民卫生出版社,2009841-846.
  • 8Addington DE,Mohamed S,Rosenheck RA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia[J].Journal of Clinical Psychiatry,2011,(01):75-80.
  • 9Kaptsan A,Dwolatzky T,Lerner V. Ziprasidonassociated depressive state in schizophrenic patients[J].Clinical Neuropharmacology,2007,(06):357-361.

二级参考文献9

  • 1[1]Keck P,Buffenstein A,Ferguson J,et al.ziprasidone Study Group.Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder:a 4-week placebo-controlled trial.Psychopharmacology,1998,140(2):173-184.
  • 2[2]Schmidt AW,Lebel LA,Johnson CG,et al.The novel antipsychotic ziprasidone has a unique human receptor binding profile compared with other agents.Soc Neurosci Abstract,1998,24(part2):2177.
  • 3[3]Allison DB,Mentore JL,Heo M,et al.Antipsychotic-induced weight gain:a comprehensive research synthesis.Am J psychiatry,1999,156(1):1686-1696.
  • 4Addington D,Addington J,Atkinson M.Apsychometric com-parison of the Calgary Depression Scalefor Schizophrenia andthe Hamilton Depression Rating Scale[].Schizophrenia Research.1996
  • 5Bressan RA,Chaves AC,Shirakawa I,et al.Validity study of the Brazilian version of the Calgary Depression Scale for Schizophrenia[].Schizophrenia Research.1998
  • 6Lancon C,Auquier P,Reine G,et al.Study of the concurrent validity of the Calgary Depression Scale for schizophyrenica(CDSS)[].Journal of Affective Disorders.
  • 7Addington D,Addington J,Schissel B.A depression rating scale for schizophrenia[].Schizophrenia Research.1990
  • 8Addington D,AddingtonJ,Maticka TE.Reliability and validity of a depression rating scale for schizophrenics[].Schizophrenia Research.1992
  • 9Addington D,Addington J,Maticka TE.Specificity of the Cal-gary Depression Scale for schizophrenica[].Schizophrenia Research.1994

共引文献37

同被引文献23

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部